

Explanations with regard to item 1 of the agenda

Presentation of the adopted annual financial statements of Heidelberg Pharma AG and the approved consolidated financial statements and the combined management report for Heidelberg Pharma AG and the Heidelberg Pharma Group, including the explanatory report of the Executive Management Board regarding the disclosures pursuant to Section 289 and Section 315a of the German Commercial Code (Handelsgesetzbuch, HGB) as well as the report of the Supervisory Board – in each case for the 2022/2023 fiscal year ended 30 November 2023

The documents mentioned in agenda item 1 are available on the Internet at <https://heidelberg-pharma.com/en/agm>.

The Supervisory Board approved the annual financial statements and the consolidated financial statements prepared by the Executive Management Board. Hence there is no need for the Annual General Meeting to adopt a resolution on this agenda item.

Ladenburg, May 2024

Heidelberg Pharma AG

The Executive Management Board